Naveed A. Sattar
Inserm
4 papers in the Anchorcite directory, published between 2016 and 2021, cited 28,413 times in total.
ORCID profileResearch topics
- Clinical practice guidelines implementation · 2 papers
- Diabetes Treatment and Management · 2 papers
- Heart Failure Treatment and Management · 2 papers
- Blood Pressure and Hypertension Studies · 1 paper
- Cardiovascular Health and Disease Prevention · 1 paper
- Health Promotion and Cardiovascular Prevention · 1 paper
Frequent co-authors
- Piotr P. Ponikowski · 3 papers
- Josep Redón · 2 papers
- Gregory Y.H. Lip · 2 papers
- Victor Aboyans · 2 papers
- Joep Perk · 2 papers
- Milton Packer · 2 papers
- Stefan D. Anker · 2 papers
- Javed Butler · 2 papers
Papers
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionEuropean Heart Journal · 2018 · 10,970 citations
The current background information and detailed discussion of the data can be found in ESC CardioMed - Section 44 Systemic hypertension ... ... Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in selecting the best…
- 2016 European Guidelines on cardiovascular disease prevention in clinical practiceEuropean Heart Journal · 2016 · 6,764 citations
Cardiovascular disease (CVD) prevention is defined as a coordinated set of actions, at the population level or targeted at an individual, that are aimed at eliminating or minimizing the impact of CVDs and their related disabilities.1 CVD remains a leading…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…
Metadata from OpenAlex (CC0).